Dermira, Inc. (DERM) Receives Consensus Recommendation of “Hold” from Analysts
Shares of Dermira, Inc. (NASDAQ:DERM) have been given a consensus recommendation of “Hold” by the ten ratings firms that are presently covering the firm, MarketBeat Ratings reports. Four analysts have rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among analysts that have issued ratings on the stock in the last year is $44.40.
DERM has been the topic of several research analyst reports. Zacks Investment Research lowered shares of Dermira from a “hold” rating to a “sell” rating in a report on Friday, July 28th. Needham & Company LLC restated a “buy” rating and issued a $46.00 price objective on shares of Dermira in a report on Tuesday, July 18th. Mizuho restated a “buy” rating and issued a $43.00 price objective (up from $40.00) on shares of Dermira in a report on Thursday, September 7th. Evercore ISI initiated coverage on shares of Dermira in a report on Thursday, June 29th. They issued an “outperform” rating and a $48.00 price objective on the stock. Finally, BidaskClub lowered shares of Dermira from a “buy” rating to a “hold” rating in a report on Monday, July 3rd.
In other Dermira news, CEO Thomas G. Wiggans sold 9,500 shares of Dermira stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $27.51, for a total value of $261,345.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Eugene A. Bauer sold 7,500 shares of Dermira stock in a transaction dated Wednesday, October 11th. The shares were sold at an average price of $30.04, for a total value of $225,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 24,300 shares of company stock valued at $682,651. 13.30% of the stock is currently owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Ardsley Advisory Partners acquired a new position in Dermira in the 2nd quarter valued at about $291,000. California State Teachers Retirement System grew its position in Dermira by 18.2% in the 2nd quarter. California State Teachers Retirement System now owns 67,518 shares of the biopharmaceutical company’s stock valued at $1,967,000 after acquiring an additional 10,400 shares in the last quarter. Bank of Nova Scotia acquired a new position in Dermira in the 2nd quarter valued at about $318,000. Platinum Investment Management Ltd. grew its position in Dermira by 28.8% in the 2nd quarter. Platinum Investment Management Ltd. now owns 57,700 shares of the biopharmaceutical company’s stock valued at $1,681,000 after acquiring an additional 12,900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company grew its position in Dermira by 51.6% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,709 shares of the biopharmaceutical company’s stock valued at $866,000 after acquiring an additional 10,110 shares in the last quarter. 97.80% of the stock is owned by institutional investors.
Dermira (DERM) traded down 3.55% on Wednesday, hitting $26.36. 177,783 shares of the stock were exchanged. Dermira has a 52-week low of $21.35 and a 52-week high of $38.75. The stock’s 50 day moving average price is $26.92 and its 200 day moving average price is $28.04. The firm’s market cap is $1.10 billion.
Dermira (NASDAQ:DERM) last issued its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.89) by ($0.04). The company had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.00 million. Dermira had a negative net margin of 408.50% and a negative return on equity of 31.66%. Equities research analysts forecast that Dermira will post ($4.20) earnings per share for the current year.
Dermira Company Profile
Dermira, Inc is a biopharmaceutical company. The Company is focused on the development of therapeutic solutions in medical dermatology to treat skin conditions, such as hyperhidrosis, psoriasis and acne. Its portfolio includes three late-stage product candidates: Cimzia (certolizumab pegol), glycopyrronium tosylate and olumacostat glasaretil.
Receive News & Ratings for Dermira Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira Inc. and related companies with MarketBeat.com's FREE daily email newsletter.